drugset / Trial / NCT02100657

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

NCT02100657

Phase 1 Completed 39 enrolled PharmaMar
NaSingle-groupOpen-labelOther

Summary

Study of Plitidepsin (Aplidin®) to determine the recommended dose (RD) of plitidepsin in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma.

Timeline

Start
2014-06
Primary completion
2018-06
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule Subcutaneous
Subject Dexamethasone Small molecule Oral
Subject Plitidepsin Peptide Intravenous

Indications